Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial
Pedro Machado(Fermi National Accelerator Laboratory), Sarah Heintzman, Isela Hernandez, Michael G. Hanna(National Hospital for Neurology and Neurosurgery), Miriam Freimer, Karina Phonekeo(University of Copenhagen), Anders Nørkær Jørgensen(University of Southern Denmark), Veena Mathew, Thomas E. Lloyd(Johns Hopkins University), Thomas Blaettler(Orphazyme (Denmark)), Emma Ciafaloni(University of Rochester Medical Center), Teresa Janecki, Ali Ciersdorff, Richard J. Barohn(University of Missouri), Sarah Jones(Health and Care Research Wales), Mazen M. Dimachkie(University of Kansas Medical Center), Aziz Shaibani(National Hospital for Neurology and Neurosurgery), Karen Bonefeld(Orphazyme (Denmark)), Mamatha Pasnoor, Omar Jawdat, Jonathan Cauchi, Michael McDermott(Unknown), Crystal Neate, Jeffrey Statland(The University of Texas at San Antonio Health Science Center), Sandhya Sasidharan, Mike Papadakis, Anders Rosholm(Orphazyme (Denmark)), Melissa Currence, Matthew Wicklund(The University of Texas at San Antonio Health Science Center), Tahseen Mozaffar(University of North Carolina at Chapel Hill), Rebecca Otutoa, MacKenzie Kaschalk, Anthony A. Amato(Brigham and Women's Hospital), Ali A. Habib(University of California, Irvine Medical Center), Andrew Heim, Summer Gibson(University of Utah), Laura Herbelin, Mark B. Bromberg(American Academy of Neurology), Kyle Mahoney, Todd Levine(Phoenix Neurological Associates), Shannon Ung, Angelina Cooper, Tim Dehli Carstensen(Orphazyme (Denmark)), Claus Sundgreen(Orphazyme (Denmark))
Cited by 35
Related Papers
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
|Annals of the Rheumatic Diseases|2017|1.6k
Variable expression of Parkinson's disease
|Neurology|1990|1.3k